The US Food and Drug Administration (FDA) has granted Fast Track designation to SPG601 for the treatment of people with Fragile X syndrome (FXS).  FXS, a known cause of autism, is the leading inherited form of intellectual disability that can produce a wide range of disabling symptoms, with many individuals requiring lifelong around-the-clock supportive care.   […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!